Andere Publikationen der Arbeitsgruppe

2017

  • Abridged version of the AWMF guideline for the medical clinical diagnostics of indoor mould exposure
    Allergo J Int DOI 10.1007/s40629-017-0013-3
    Gerhard A. Wiesmüller, Birger Heinzow,Ute Aurbach, Karl-Christian Bergmann, Albrecht Bufe, Walter Buzina, Oliver A. Cornely, et al.

    Abstract This article is an abridged version of the AWMF mould guideline “Medical clinical diagnosticsof indoor mould exposure” presented in April 2016 by the German Society of Hygiene, Environmental Medicine and Preventive Medicine (Gesellschaft für Hygiene, Umweltmedizin und Präventivmedizin, GHUP), in collaboration with the above-mentioned scientific medical societies, German and Austrian societies, medical associations and experts. Indoor mould growth is a potential health risk, even if a quantitative and/or causal relationship between the occurrence of individual mould species and health problems has yet to be established. Apart from allergic bronchopulmonary aspergillosis (ABPA) and mould-caused mycoses, only sufficient evidence for an association between moisture/mould damage and the following health effects has been established: allergic respiratory disease, asthma (manifestation, progression and exacerbation), allergic rhinitis, hypersensitivity pneumonitis (extrinsic allergic alveolitis), and increased likelihood of respiratory infections/bronchitis. In this context the sensitizing potential of moulds is obviously low compared to other environmental allergens. Recent studies show a comparatively low sensitizing prevalence of 3–10% in the general population across Europe. Limited or suspected evidence for an association exist with respect to mucous membrane irritation and atopic eczema (manifestation, progression and exacerbation). Inadequateor insufficient evidence for an association exist for chronic obstructive pulmonary disease, acute idiopathic pulmonary hemorrhage in children, rheumatism/arthritis, sarcoidosis and cancer. The risk of infection posed by moulds regularly occurring indoors is low for healthy persons; most species are in risk group 1 and a few in risk group 2 (Aspergillus fumigatus, A. flavus) of the German Biological Agents Act (Biostoffverordnung). Only moulds that are potentially able to form toxins can be triggers of toxic reactions. Whether or not toxin formation occurs in individual cases is determined by environmental and growth conditions, above all the substrate. In the case of indoor moisture/mould damage, everyone can be affected by odour effects and/or mood disorders. However, this is not a health hazard. Predisposing factors for odour effects can include genetic and hormonal influences, imprinting, context and adaptation effects. Predisposing factors for mood disorders may include environmental concerns, anxiety, condition, and attribution, as well as various diseases. Risk groups to be protected particularly with regard to an infection risk are persons on immunosuppression according to the classification of the German Commission for Hospital Hygiene and Infection Prevention (Kommission für Krankenhaushygiene und Infektionsprävention,KRINKO) at the Robert Koch- Institute (RKI) and persons with cystic fibrosis (mucoviscidosis); with regard to an allergic risk, persons with cystic fibrosis (mucoviscidosis) and patients with bronchial asthma should be protected. The rational diagnostics include the medical history, physical examination, and conventional allergy diagnostics including provocation tests if necessary;
    undefinedHere you can find the publication.

2016

  • AWMF-Schimmelpilz-Leitlinie (Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften) "Medizinsch klinische Diagnostik bei Schimmelpilzexposition in Innenräumen" AWMF-Register-Nr. 161/001 (http://www.awmf.org/leitlinien/detail/ll/161-001.html) - Kurzfassung für von einem Schimmelpilzbefall Betroffene -

G. A. Wiesmüller1, 2, a, b, B. Heinzow3, a, b, U. Aurbach4, a, K.-C. Bergmann5, a, bet al.
undefinedHier können Sie die Endfassung der Laieninformation zur AWMF-Leitlinie herunterladen.

  • First comparison of symptom data with allergen content (Bet v 1 and Phl p 5 measurements) and pollen data from four European regions during 2009–2011

Katharina Bastl, Maximilian Kmenta, Anna-Mari Pessi, Marje Prank, Annika Saarto, Mikhail Sofiev, Karl-Christian Bergmann, Jeroen T.M. Buters, Michel Thibaudon, Siegfried Jäger, Uwe Berger
Science of the Total Environment (2016); 548–549; 229–235.
Abstract. Background:
The level of symptoms in pollen allergy sufferers and users of the Patient's Hayfever Diary (PHD),does not directly reflect the total amount of pollen in the air. It is necessary to explain the symptom load and thus the development of allergic symptoms and to determine which environmental factors, besides the pollen load, influence variables. It seems reasonable to suspect allergen content because the amount of allergen varies throughout seasons and regions and is not always correlated with the total pollen amount. Methods: Data on the allergen content of ambient air (Bet v 1 and Phl p 5) from 2009 until 2011 was used to compare the respective pollen and symptom loads for study regions in Austria, Germany, France and Finland. Results: Our findings suggest that allergen amount (Bet v 1/Phl p 5) has a strong but regionally dependent impact on the symptom load of pollen allergy sufferers. Peak symptomloads can be traced with peak allergen loads. The influence of other important aeroallergens should also be assessed during the pollen season.
undefinedHere you can download the publication.

Aktuelles:

Wochenpollenvorhersage Florian - 22.03.2017

22.03.2017

Eschenblüte beginnt - Birke schon in den Startlöchern

Wochenpollenvorhersage Johanna - 15.03.2017

15.03.2017

Kurzzeitige Entlastung bei den Hauptallergenen.

Wochenpollenvorhersage Angelika - 08.03.2017

08.03.2017

Erle dominiert den Pollenflug!